What is ENTA's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.36B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for ENTA?

P/E (TTM) is n/a and 52-week range is $10.20 to $17.15 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s ENTA figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for ENTA?

The company profile lists revenue (TTM) near $65M, net income (TTM) near $-6.32B, EPS (TTM) near $-2.41 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Enanta Pharmaceuticals Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Watertown, Massachusetts, US, 29.1M shares outstanding, ISIN US29251M1062 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Enanta Pharmaceuticals Inc

$ENTA

Health Care · Biotechnology

IR Run Scenarios

$12.50

+3.31%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Enanta Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery and development of small molecule drugs for the treatment of viral infections and liver diseases. The company is headquartered in Watertown, Massachusetts and currently employs 120 full-time employees. The company went IPO on 2013-03-21. The firm is engaged in the discovery and development of small molecule drugs with an emphasis on indications in virology and immunology. The Company’s clinical programs are focused on respiratory syncytial virus (RSV) and its earlier-stage immunology pipeline aims to develop treatments for inflammatory diseases by targeting key drivers of the type 2 immune response, including receptor tyrosine kinase (KIT) and STAT6 inhibition. The firm has two clinical-stage product candidates for RSV, which are zelicapavir and EDP-323. Glecaprevir, a protease inhibitor discovered by the Company, is part of one of the treatment regimens for curing chronic hepatitis c virus (HCV) infection and is sold by AbbVie in various countries under the tradenames MAVYRET (U.S.) and MAVIRET (ex-U.S.) (glecaprevir/pibrentasvir). The firm also has development programs in virology for SARS-CoV-2 and Hepatitis B virus.

Employees

120

Website

www.enanta.com/

IPO

2013-03-21

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)